Literature DB >> 9659448

Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration.

J F Aupetit1, D Frassati, B Bui-Xuan, M Freysz, G Faucon, Q Timour.   

Abstract

OBJECTIVES: To investigate the prevention of ventricular fibrillation with a beta-adrenergic receptor (beta-AR) antagonist in anaesthetized, open-chest pigs in a model of ischaemia, intended to reproduce what happens either in anginal attack or in the first hour of infarction.
METHODS: Ventricular fibrillation threshold (VFT) was determined with trains of diastolic stimuli of 100 ms duration delivered by a subepicardial electrode inserted in the area subjected to ischaemia. Ischaemia was obtained by the complete occlusion of the left anterior descending coronary artery, either near its origin during brief but increasing periods (30, 60, 90, 120, 150, 180, 240, 300 s), or half-way from its origin for a much longer time (more than 60 min).
RESULTS: During transient proximal occlusion and isoprenaline infusion (0.25 microgram/kg/min), propranolol (50 micrograms/kg plus 2 micrograms/kg/min) attenuated both tachycardia and the fall in VFT to 0 mA. The shortening of MAP duration accompanying depolarization of the fibres was concurrently slowed down, and time to fibrillation prolonged (122 +/- 15 to 262 +/- 14 s, p < 0.001). In the absence of isoprenaline infusion, propranolol exerted similar effects, but to a lesser degree, in proportion to heart rate dependent on sympathetic activity. In contrast, it became unable to raise VFT before and during ischaemia, when heart rate was kept constant by pacing. After persistent midportion occlusion, significant differences in VFT were found only at the 5th min, depending on whether heart rate was accelerated by isoprenaline (0.8 +/- 0.2 mA), left normal (1.8 +/- 0.3 mA) or slowed down by propranolol (1.6 +/- 0.3 mA). Later on, especially after 15 and 25 min of ischaemia, VFT, which was below 1.0 mA, did not appear to be influenced by the activation or blockade of beta-ARs: spontaneous fibrillations were observed in the same number in this period with or without the administration of propranolol. Beyond 30 min after occlusion, the rise in VFT, subsequent to the first irreversible cell damage, also occurred in the same way.
CONCLUSIONS: The prevention of ischaemic ventricular fibrillation by a beta-AR antagonist, judged from VFT, is easily checked experimentally when ischaemia is only transitory, especially if sympathetic activity is high. The maintenance of VFT at a relatively high level is essentially related to the depressant effect on the sinus rate. The same animal model does not give support to an effective protection in the first hour of infarction. However, the control of heart rate may also be beneficial in these circumstances by attenuating systemic haemodynamic disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659448     DOI: 10.1016/s0008-6363(97)00304-0

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  10 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.

Authors:  John R Kapoor; Paul A Heidenreich
Journal:  Curr Heart Fail Rep       Date:  2012-06

3.  Racing to the flatline: heart rate and β-adrenergic stimulation quicken the pace.

Authors:  Matthew Kay; Sarah Kuzmiak-Glancy; Jack Rogers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

4.  Effect of Resting Heart Rate on All-Cause Mortality and Cardiovascular Events According to Age.

Authors:  Kuibao Li; Chonghua Yao; Xinchun Yang; Lei Dong
Journal:  J Am Geriatr Soc       Date:  2016-12-30       Impact factor: 5.562

5.  β-Adrenergic stimulation and rapid pacing mutually promote heterogeneous electrical failure and ventricular fibrillation in the globally ischemic heart.

Authors:  Vivek Garg; Tyson Taylor; Mark Warren; Paul Venable; Katie Sciuto; Junko Shibayama; Alexey Zaitsev
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-20       Impact factor: 4.733

6.  Beta-blocker use and the changing epidemiology of out-of-hospital cardiac arrest rhythms.

Authors:  Scott T Youngquist; Amy H Kaji; James T Niemann
Journal:  Resuscitation       Date:  2007-10-31       Impact factor: 5.262

7.  Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia.

Authors:  L Dehina; F Vaillant; A Tabib; B Bui-Xuan; Ph Chevalier; N Dizerens; C Bui-Xuan; J Descotes; V Blanc-Guillemaud; L Lerond; Q Timour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-22       Impact factor: 3.000

Review 8.  Heart rate reduction in coronary artery disease and heart failure.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Nat Rev Cardiol       Date:  2016-05-26       Impact factor: 32.419

9.  Hepatic c-Jun regulates glucose metabolism via FGF21 and modulates body temperature through the neural signals.

Authors:  Fei Xiao; Yajie Guo; Jiali Deng; Feixiang Yuan; Yuzhong Xiao; Lijian Hui; Yu Li; Zhimin Hu; Yuncai Zhou; Kai Li; Xiao Han; Qichen Fang; Weiping Jia; Yan Chen; Hao Ying; Qiwei Zhai; Shanghai Chen; Feifan Guo
Journal:  Mol Metab       Date:  2018-12-12       Impact factor: 7.422

10.  Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias.

Authors:  Fu Siong Ng; Iqbal T Shadi; Nicholas S Peters; Alexander R Lyon
Journal:  J Mol Cell Cardiol       Date:  2013-02-09       Impact factor: 5.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.